CD133 is expressed on immature hematopoietic stem and progenitor cells but is not found on mature blood cells. In contrast to the CD34 antigen, CD133 is not expressed by late progenitors such as pre-B cells, CFU-E, and CFU-G. The stem cell marker CD133 was formerly known as AC133.
The CliniMACS® CD133 Product Line consists of murine anti-CD133 monoclonal antibodies conjugated to superparamagnetic iron dextran particles.
One vial contains 7.5 mL sterile, non‑pyrogenic solution.
The performance of the CliniMACS CD133 Product Line depends on the individual separati
Flow cytometric analysis of CD133–enriched cells from a mobilized leukapheresis product using the CliniMACS CD133 System.
Flow cytometric analysis of CD133–enriched stem cells from a bone marrow aspirate using the CliniMACS CD133 System.
CD133 is expressed on immature hematopoietic stem and progenitor cells but is not found on mature blood cells. In contrast to the CD34 antigen, CD133 is not expressed by late progenitors such as pre-B cells, CFU-E, and CFU-G. The stem cell marker CD133 was formerly known as AC133.
The CliniMACS® CD133 Product Line consists of murine anti-CD133 monoclonal antibodies conjugated to superparamagnetic iron dextran particles.
One vial contains 7.5 mL sterile, non‑pyrogenic solution.
The performance of the CliniMACS CD133 Product Line depends on the individual separation strategy. For information on respective capacities, refer to the CliniMACS User Manual or contact your local representative.
Please inquire about required CliniMACS System components and accessories.
The CliniMACS CD133 Product Line was developed for the enrichment of CD133+ cells from human heterogeneous hematologic cell populations in combination with the CliniMACS System.
CD133+ stem cells are investigated in various areas of regenerative medicine, such as cardiovascular diseases, liver diseases and peripheral artery diseases.1–9
Besides the interest in non-hematopoietic applications, CD133+ stem cell enrichment is performed to provide an allogeneic stemcell graft highly purified for CD133+ cells and depleted of unwanted cells.10–15
In autologous transplantation, CD133+ progenitor cells can be enriched in order to passively remove tumor cells from the graft (purging).16
The CliniMACS® System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.
In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for in vitro use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations - e.g., for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") - must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.
In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE) or FDA approval.
CR/GMP products are for ex vivo cell processing only, and are not intended for human in vivo applications. CR/GMP products are designed, manufactured and tested under an ISO 13485 quality management system and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials. The manufacturing and testing of CR/GMP products of biological origin are in compliance with EP chapter 5.2.12 for “Raw materials of biological origin for the production of cell-based and gene therapy medicinal products”.
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
- Schulte am Esch 2nd, J. et al. (2005) Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells 23 (4): 463-470
- Klein, H. M. et al. (2007) Intramyocardial implantation of CD133+ stem cells improved cardiac function without bypass surgery. Heart Surg. Forum 10: E66-69
- Stamm, C. et al. (2003) Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 4, 361 (9351): 45-46
- Lang, P. et al. (2004) Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors. Br J Haematol 124: 72-79
- Cañizo, M. C. et al. (2007) Peripheral endothelial progenitor cells (CD133+) for therapeutic vasculogenesis in a patient with critical limb ischemia. One year follow-up. Cytotherapy 9 (1): 99-102
- Clinical Trials.gov : NCT00950274
- Bitan, M. et al. (2005) Successful transplantation of haploidentically mismatched peripheral blood stem cells using CD133+-purified stem cells. Exp. Hematol. 33: 713-718
- Bartunek et al. (2005) Circulation 30: 178-183
- Lang, P. et al. (2004) Correction of persistent thrombocytopenia by a boost of CD133+ selected stem cells in a patient transplanted for Wiskott-Aldrich syndrome 10 years ago. Bone Marrow Transplant. 33 (1): 879-880
- Bornhäuser, M. et al. (2005) Rapid reconstitution of dendritic cells after allogeneic transplantation of CD133+ selected hematopoietic stem cells. Leukemia 19: 161-165
- Klein (2007) Eur. Cardiovasc. Dis. 1: 123-125
- Peled, T. et al. (2004) Pre-clinical development of cord blood-derived progenitor cell graft expanded ex vivo with cytokines and the polyamine copper chelator tetraethylenepentamine. Cytotherapy 6: 344-355
- Fürst, G. et al. (2007) Portal vein embolization and autologous CD133+ bone marrow stem cells for liver regeneration: initial experience. J Immunother 243 (1): 171-179
- Stamm, C. et al. (2007) Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. J. Thorac. Cardiovasc. Surg. 133: 717-725
- Koehl, S. et al. (2002) Autologous transplantation of CD133 selected hematopoietic progenitor cells in a pediatric patient with relapsed leukemia. Bone Marrow Transplant. 29: 927-930
- Gordon, P. R. et al. (2003) Large-scale isolation of CD133+ progenitor cells from G-CSF mobilized peripheral blood stem cells. Bone Marrow Transplant. 31: 17-22
You have previously chosen International as your location.
What do you want to do?